<p>AllianceBernstein（紐約證券交易所代碼：AB - 獲取免費報告）在週三發佈的研究報告中，巴克萊的股票研究分析師將其目標價格從 34.00 美元上調至 36.00 美元。該公司目前對這家資產管理公司的股票給予 “持平” 評級。巴克萊的目標價格暗示該公司當前價格有 3.05% 的下行潛力。</p>
<p>獲取 <strong>AllianceBernstein</strong> 的提醒：</p>
<ul>
<li>3 只逆勢而上的生物製藥股票</li>
</ul>
<p>其他幾家券商最近也對 AB 發佈了報告。Evercore ISI 將 AllianceBernstein 的目標價格從 41.00 美元下調至 38.00 美元，並在 4 月 11 日的研究報告中給予該公司 “跑贏大盤” 的評級。美國銀行將 AllianceBernstein 的股票評級從 “買入” 下調至 “中性”，並在 4 月 3 日的研究報告中將該公司的目標價格從 42.00 美元下調至 38.00 美元。Sanford C. Bernstein 在 4 月 3 日的報告中將 AllianceBernstein 的股票評級從 “買入” 下調至 “中性”，並設定了 38.00 美元的目標價格。最後，TD Cowen 在 4 月 9 日的報告中將 AllianceBernstein 的目標價格從 37.50 美元下調至 34.00 美元，並對該股票給予 “持有” 評級。四位研究分析師對該股票給予了持有評級，兩位分析師對該公司給予了買入評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “持有”，平均目標價格為 37.50 美元。</p>
<p><strong>閲讀我們關於 AllianceBernstein 的最新研究報告</strong></p>
<h2>AllianceBernstein 股價下跌 1.7%</h2>
<ul>
<li>MarketBeat 週報 – 03/24 - 03/28</li>
</ul>
<p>AB 的股票在週三開盤價為 37.13 美元。AllianceBernstein 的 1 年最低價為 30.57 美元，1 年最高價為 41.37 美元。該公司的市值為 41 億美元，市盈率為 9.98，市盈增長比率為 0.78，貝塔值為 0.97。該公司的 50 日移動平均價格為 36.99 美元，200 日移動平均價格為 36.94 美元。</p>
<p>AllianceBernstein（紐約證券交易所代碼：AB - 獲取免費報告）最近在 2 月 6 日發佈了季度財報。該資產管理公司報告季度每股收益為 1.05 美元，超出市場共識預期的 0.87 美元，超出幅度為 0.18 美元。AllianceBernstein 的淨利潤率為 9.46%，股本回報率為 17.88%。研究分析師平均預測 AllianceBernstein 在當前年度的每股收益為 3.58 美元。</p>
<h2>AllianceBernstein 的機構交易</h2>
<ul>
<li>AbbVie 股票通過進入減肥市場提升投資組合</li>
</ul>
<p>一些對沖基金最近調整了對該公司的持股。FMR LLC 在第四季度將其在 AllianceBernstein 的持股增加了 19.0%。FMR LLC 目前擁有 3,110,304 股該資產管理公司的股票，價值 115,361,000 美元，此前在該期間內增持了 496,923 股。American Century Companies Inc.在第四季度將其在 AllianceBernstein 的持股增加了 1.1%。American Century Companies Inc.目前擁有 3,026,102 股該資產管理公司的股票，價值 112,238,000 美元，此前在上個季度增持了 33,888 股。摩根大通在第四季度將其在 AllianceBernstein 的持股增加了 18.1%。摩根大通目前擁有 2,899,762 股該資產管理公司的股票，價值 107,552,000 美元，此前在上個季度增持了 445,398 股。Jennison Associates LLC 在第四季度將其在 AllianceBernstein 的持股增加了 7.0%。Jennison Associates LLC 目前擁有 939,649 股該資產管理公司的股票，價值 34,852,000 美元，此前在上個季度增持了 61,326 股。最後，Natixis 在第四季度將其在 AllianceBernstein 的持股增加了 16.4%。Natixis 目前擁有 660,700 股該資產管理公司的股票，價值 24,505,000 美元，此前在該期間內增持了 93,300 股。機構投資者持有該公司 19.25% 的股票。</p>
<h2>關於 AllianceBernstein</h2>
<p>（獲取免費報告）</p>
<p>AllianceBernstein Holding L.P.是一家公開上市的投資管理公司。該公司是相關顧問，管理着為客户量身定製的獨立投資組合。該公司主要投資於普通股和優先股、認股權證和可轉換證券、政府和企業固定收益證券、商品、貨幣、房地產相關資產和通脹保護證券。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票比 AllianceBernstein 更好</li>
<li>什麼是股息競爭者？投資股息競爭者</li>
<li>3 家高價值公司具有三位數的上漲潛力</li>
<li>期權交易 - 理解行使價格</li>
<li>強生的收益好於壞——現在是買入的時候嗎？</li>
<li>三隻值得買入和持有的醫療保健股息股票</li>
<li>今年迄今表現最差的兩隻標準普爾 500 股票：買入、賣出還是迴避？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFC?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFC"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 AllianceBernstein 嗎？</h2>
<p>在考慮 AllianceBernstein 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前買入……而 AllianceBernstein 並不在名單上。</p>
<p>雖然 AllianceBernstein 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>巴克萊將 AllianceBernstein（紐約證券交易所代碼：AB）的目標價從 34.00 美元上調至 36.00 美元，維持 “持平” 評級。這意味着相較於當前價格，存在 3.05% 的潛在下行空間。其他券商也調整了他們的評級，Evercore ISI 設定的目標價為 38.00 美元，而美國銀行也將其目標價下調至 38.00 美元。AllianceBernstein 的股票開盤價為 37.13 美元，1 年區間為 30.57 美元至 41.37 美元。分析師預測當前年的每股收益為 3.58 美元</p>

<p>AllianceBernstein (NYSE:AB - Get Free Report) had its price objective boosted by equities research analysts at Barclays from $34.00 to $36.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has an &#34;equal weight&#34; rating on the asset manager's stock. Barclays's price target suggests a potential downside of 3.05% from the company's current price.</p>
<div class="lb-trans"><p>AllianceBernstein（紐約證券交易所代碼：AB - 獲取免費報告）在週三發佈的研究報告中，巴克萊的股票研究分析師將其目標價格從 34.00 美元上調至 36.00 美元。該公司目前對這家資產管理公司的股票給予 “持平” 評級。巴克萊的目標價格暗示該公司當前價格有 3.05% 的下行潛力。</p>
</div><p>Get <strong>AllianceBernstein</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>AllianceBernstein</strong> 的提醒：</p>
</div><ul>
<li>3 Biopharmaceutical Stocks Bucking the Sell-Off</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只逆勢而上的生物製藥股票</li>
</ul>
</div><p>Several other brokerages also recently issued reports on AB. Evercore ISI reduced their price objective on AllianceBernstein from $41.00 to $38.00 and set an &#34;outperform&#34; rating for the company in a research note on Friday, April 11th. Bank of America lowered shares of AllianceBernstein from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and dropped their price objective for the company from $42.00 to $38.00 in a research note on Thursday, April 3rd. Sanford C. Bernstein cut shares of AllianceBernstein from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and set a $38.00 price objective for the company. in a report on Thursday, April 3rd. Finally, TD Cowen lowered their price objective on AllianceBernstein from $37.50 to $34.00 and set a &#34;hold&#34; rating on the stock in a report on Wednesday, April 9th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of &#34;Hold&#34; and an average price target of $37.50.</p>
<div class="lb-trans"><p>其他幾家券商最近也對 AB 發佈了報告。Evercore ISI 將 AllianceBernstein 的目標價格從 41.00 美元下調至 38.00 美元，並在 4 月 11 日的研究報告中給予該公司 “跑贏大盤” 的評級。美國銀行將 AllianceBernstein 的股票評級從 “買入” 下調至 “中性”，並在 4 月 3 日的研究報告中將該公司的目標價格從 42.00 美元下調至 38.00 美元。Sanford C. Bernstein 在 4 月 3 日的報告中將 AllianceBernstein 的股票評級從 “買入” 下調至 “中性”，並設定了 38.00 美元的目標價格。最後，TD Cowen 在 4 月 9 日的報告中將 AllianceBernstein 的目標價格從 37.50 美元下調至 34.00 美元，並對該股票給予 “持有” 評級。四位研究分析師對該股票給予了持有評級，兩位分析師對該公司給予了買入評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “持有”，平均目標價格為 37.50 美元。</p>
</div><p><strong>Read Our Latest Research Report on AllianceBernstein</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 AllianceBernstein 的最新研究報告</strong></p>
</div><h2>AllianceBernstein Trading Down 1.7 %</h2>
<div class="lb-trans"><h2>AllianceBernstein 股價下跌 1.7%</h2>
</div><ul>
<li>MarketBeat Week in Review – 03/24 - 03/28</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週報 – 03/24 - 03/28</li>
</ul>
</div><p>Shares of AB opened at $37.13 on Wednesday. AllianceBernstein has a 1-year low of $30.57 and a 1-year high of $41.37. The stock has a market capitalization of $4.10 billion, a P/E ratio of 9.98, a P/E/G ratio of 0.78 and a beta of 0.97. The business's 50-day moving average price is $36.99 and its 200 day moving average price is $36.94.</p>
<div class="lb-trans"><p>AB 的股票在週三開盤價為 37.13 美元。AllianceBernstein 的 1 年最低價為 30.57 美元，1 年最高價為 41.37 美元。該公司的市值為 41 億美元，市盈率為 9.98，市盈增長比率為 0.78，貝塔值為 0.97。該公司的 50 日移動平均價格為 36.99 美元，200 日移動平均價格為 36.94 美元。</p>
</div><p>AllianceBernstein (NYSE:AB - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The asset manager reported $1.05 EPS for the quarter, beating the consensus estimate of $0.87 by $0.18. AllianceBernstein had a net margin of 9.46% and a return on equity of 17.88%. On average, research analysts predict that AllianceBernstein will post 3.58 earnings per share for the current year.</p>
<div class="lb-trans"><p>AllianceBernstein（紐約證券交易所代碼：AB - 獲取免費報告）最近在 2 月 6 日發佈了季度財報。該資產管理公司報告季度每股收益為 1.05 美元，超出市場共識預期的 0.87 美元，超出幅度為 0.18 美元。AllianceBernstein 的淨利潤率為 9.46%，股本回報率為 17.88%。研究分析師平均預測 AllianceBernstein 在當前年度的每股收益為 3.58 美元。</p>
</div><h2>Institutional Trading of AllianceBernstein</h2>
<div class="lb-trans"><h2>AllianceBernstein 的機構交易</h2>
</div><ul>
<li>AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market</li>
</ul>
<div class="lb-trans"><ul>
<li>AbbVie 股票通過進入減肥市場提升投資組合</li>
</ul>
</div><p>A number of hedge funds have recently modified their holdings of the company. FMR LLC lifted its holdings in shares of AllianceBernstein by 19.0% during the 4th quarter. FMR LLC now owns 3,110,304 shares of the asset manager's stock worth $115,361,000 after acquiring an additional 496,923 shares during the period. American Century Companies Inc. boosted its holdings in AllianceBernstein by 1.1% during the fourth quarter. American Century Companies Inc. now owns 3,026,102 shares of the asset manager's stock valued at $112,238,000 after purchasing an additional 33,888 shares in the last quarter. JPMorgan Chase &amp; Co. raised its holdings in shares of AllianceBernstein by 18.1% in the 4th quarter. JPMorgan Chase &amp; Co. now owns 2,899,762 shares of the asset manager's stock worth $107,552,000 after buying an additional 445,398 shares in the last quarter. Jennison Associates LLC boosted its stake in AllianceBernstein by 7.0% in the 4th quarter. Jennison Associates LLC now owns 939,649 shares of the asset manager's stock valued at $34,852,000 after buying an additional 61,326 shares in the last quarter. Finally, Natixis grew its position in AllianceBernstein by 16.4% in the fourth quarter. Natixis now owns 660,700 shares of the asset manager's stock valued at $24,505,000 after acquiring an additional 93,300 shares during the period. Institutional investors own 19.25% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金最近調整了對該公司的持股。FMR LLC 在第四季度將其在 AllianceBernstein 的持股增加了 19.0%。FMR LLC 目前擁有 3,110,304 股該資產管理公司的股票，價值 115,361,000 美元，此前在該期間內增持了 496,923 股。American Century Companies Inc.在第四季度將其在 AllianceBernstein 的持股增加了 1.1%。American Century Companies Inc.目前擁有 3,026,102 股該資產管理公司的股票，價值 112,238,000 美元，此前在上個季度增持了 33,888 股。摩根大通在第四季度將其在 AllianceBernstein 的持股增加了 18.1%。摩根大通目前擁有 2,899,762 股該資產管理公司的股票，價值 107,552,000 美元，此前在上個季度增持了 445,398 股。Jennison Associates LLC 在第四季度將其在 AllianceBernstein 的持股增加了 7.0%。Jennison Associates LLC 目前擁有 939,649 股該資產管理公司的股票，價值 34,852,000 美元，此前在上個季度增持了 61,326 股。最後，Natixis 在第四季度將其在 AllianceBernstein 的持股增加了 16.4%。Natixis 目前擁有 660,700 股該資產管理公司的股票，價值 24,505,000 美元，此前在該期間內增持了 93,300 股。機構投資者持有該公司 19.25% 的股票。</p>
</div><h2>About AllianceBernstein</h2>
<div class="lb-trans"><h2>關於 AllianceBernstein</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>AllianceBernstein Holding L.P. is a publicly owned investment manager. The firm is a related adviser The firm manages separate client focused portfolios for its clients. The firm primarily invests in common and preferred stocks, warrants and convertible securities, government and corporate fxed-income securities, commodities, currencies, real estate-related assets and infation-protected securities.</p>
<div class="lb-trans"><p>AllianceBernstein Holding L.P.是一家公開上市的投資管理公司。該公司是相關顧問，管理着為客户量身定製的獨立投資組合。該公司主要投資於普通股和優先股、認股權證和可轉換證券、政府和企業固定收益證券、商品、貨幣、房地產相關資產和通脹保護證券。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than AllianceBernstein</li>
<li>What Are Dividend Contenders? Investing in Dividend Contenders</li>
<li>3 High-Value Companies With Triple-Digit Upside Potential</li>
<li>Options Trading - Understanding Strike Price</li>
<li>Johnson &amp; Johnson Earnings Were More Good Than Bad—Time to Buy?</li>
<li>The Top 3 Healthcare Dividend Stocks to Buy and Hold</li>
<li>The 2 Worst Performing S&amp;P 500 Stocks YTD: Buy, Sell, or Avoid?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票比 AllianceBernstein 更好</li>
<li>什麼是股息競爭者？投資股息競爭者</li>
<li>3 家高價值公司具有三位數的上漲潛力</li>
<li>期權交易 - 理解行使價格</li>
<li>強生的收益好於壞——現在是買入的時候嗎？</li>
<li>三隻值得買入和持有的醫療保健股息股票</li>
<li>今年迄今表現最差的兩隻標準普爾 500 股票：買入、賣出還是迴避？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFC" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=AB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in AllianceBernstein Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 AllianceBernstein 嗎？</h2>
</div><p>Before you consider AllianceBernstein, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 AllianceBernstein 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AllianceBernstein wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前買入……而 AllianceBernstein 並不在名單上。</p>
</div><p>While AllianceBernstein currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 AllianceBernstein 目前在分析師中獲得 “持有” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

巴克萊分析師表示，AllianceBernstein（紐約證券交易所代碼：AB）的股價預計將會上漲